342 



We encourage independent investigators to publish their results 

 in reputable journals, preferably peer-reviewed. The industry exer- 

 cises no control over our activities, over the granting of funds for 

 basic research, or the sort of research that will be pursued. 



The Council has never diverted any research into special pro- 

 grams or special projects for the purpose of suppressing research. 



Those who have worked with the Council over the years, as I 

 have, recognize these allegations to be untrue. Let me try to give 

 you some facts to replace these erroneous speculations. 



The Council is a private, nonprofit organization that sponsors re- 

 search into questions of tobacco use and health. It was founded in 

 1954 as the Tobacco Industry Research Committee, later changing 

 its name to the current one. 



It has been funded primarily by the five major tobacco manufac- 

 turers over the years. The awards are approximately $20 million 

 per year at the present time, making the Council for, CTR one of 

 the largest private granting agencies in the Nation. We have 

 awarded over $220 million over the years, funding some 1,380 

 projects by about 1,000 biomedical investigators. All this research 

 has been performed by independent scientists. 



The Council for Tobacco Research does not accomplish research 

 on its own. We have no research facilities. We are simply a funding 

 agency for independently accomplished private research. 



The funded research has been done at preeminent medical insti- 

 tutions throughout this country and abroad. We have grants at 

 Harvard university, Johns Hopkins, Duke University, the Univer- 

 sity of Texas, the Mayo Clinic, Scripps Research Institute, the Na- 

 tional Institutes of Health, and several Veteran's Administration 

 hospital facilities. 



A large number, perhaps the overwhelming majority of the re- 

 search projects that we have funded, have been co-funded by other 

 distinguished granting agencies including the National Institutes of 

 Health, and its National Cancer Institute, also by the Environ- 

 mental Protection Agency, the American Cancer Society, the Amer- 

 ican Lung Association, and the American Heart Association. 



I am sure if you have perused the 30 copies of the annual reports 

 that we have provided for you you will see the nature of the re- 

 search and also the credits of those efforts both to the CTR and si- 

 multaneously to other agencies. 



The funding is provided for research in certain key biomedical 

 areas. Cancer leads the list. Over half of our grants at the present 

 time are devoted to some aspect of malignant disease. Cardio- 

 vascular diseases have played an important role. We are support- 

 ing research in cellular and molecular biology and developmental 

 biology. 



Epidemiology has been an interest, though fading, because epi- 

 demiologic studies are not at the cutting edge of science any longer. 



We are progressively funding research into areas of genetics, im- 

 munology, the neurosciences, and I might mention that currently 

 we are sponsoring a conference here in Washington, DC, which is 

 under the auspices of the New York Academy of Sciences and it 

 deals with the functional diversity of interacting receptors. This 

 conference is a special conference of the New York Academy. 



